Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

VERV

Verve Therapeutics Inc

Oct 11 • 04:00PM ET

4.67

Dollar change +0.07
Percentage change 1.52	%

Healthcare • Biotechnology • USA • NASD

Peers: BEAM BLRX CLLS CRBU CRSP DTIL EDIT NTLA QURE SGMO

| Held by: VTI XBI IWM VXF VB VBK IWN IBB VTWO KOMP

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.60	Insider Own	26.18%	Shs Outstand	81.97M	Perf Week	-6.60%
Market Cap	395.18M	Forward P/E	-	EPS next Y	-2.87	Insider Trans	0.34%	Shs Float	62.47M	Perf Month	-17.35%
Income	-192.65M	PEG	-	EPS next Q	-0.68	Inst Own	69.01%	Short Float	27.05%	Perf Quarter	-34.78%
Sales	20.65M	P/S	19.14	EPS this Y	17.45%	Inst Trans	-8.74%	Short Ratio	12.32	Perf Half Y	-38.55%
Book/sh	6.46	P/B	0.72	EPS next Y	-11.55%	ROA	-29.87%	Short Interest	16.90M	Perf Year	-61.94%
Cash/sh	6.81	P/C	0.69	EPS next 5Y	-	ROE	-38.10%	52W Range	4.30 - 20.12	Perf YTD	-66.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-67.06%	ROI	-31.67%	52W High	-76.79%	Beta	1.81
Dividend TTM	-	Quick Ratio	14.64	Sales past 5Y	126.44%	Gross Margin	61.18%	52W Low	8.48%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	14.64	EPS Y/Y TTM	18.15%	Oper. Margin	-1075.00%	RSI (14)	40.50	Volatility	6.23% 6.40%
Employees	255	Debt/Eq	0.13	Sales Y/Y TTM	279.70%	Profit Margin	-933.02%	Recom	1.20	Target Price	25.11
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	32.14%	Payout	-	Rel Volume	0.63	Prev Close	4.60
Sales Surprise	178.66%	EPS Surprise	12.89%	Sales Q/Q	219.73%	Earnings	Aug 08 BMO	Avg Volume	1.37M	Price	4.67
SMA20	-5.53%	SMA50	-10.80%	SMA200	-43.83%	Trades		Volume	860,714	Change	1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-24	Initiated	H.C. Wainwright	Buy	$15
Apr-13-23	Initiated	Canaccord Genuity	Buy	$29
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral	$21
Dec-15-22	Initiated	Goldman	Sell	$13
Oct-06-22	Initiated	Credit Suisse	Neutral	$48
Aug-25-22	Upgrade	Stifel	Hold → Buy	$32 → $56
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$48
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$42
Sep-24-21	Initiated	Stifel	Hold	$58
Jul-12-21	Initiated	William Blair	Outperform	$92
Jul-12-21	Initiated	JP Morgan	Neutral	$50
Jul-12-21	Initiated	Jefferies	Buy	$72
Jul-12-21	Initiated	Guggenheim	Buy	$84

Show Previous Ratings

Oct-11-24 06:15AM	Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERV (PR Newswire)
Oct-03-24 04:56AM	Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5? (Insider Monkey)
Oct-02-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:15AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
Sep-20-24 04:40PM	Jim Cramer on Vertiv Holdings (VRT): I Think Its A Winner (Insider Monkey)
01:15AM	Loading…
Sep-12-24 01:15AM	Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc (GuruFocus.com)
Sep-08-24 04:51PM	Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers (Insider Monkey)
11:49AM	10 Worst ARK Stocks To Buy According To Short Sellers (Insider Monkey)
Sep-05-24 08:30AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire) -9.34%
Sep-03-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.25%
Aug-08-24 10:00AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
08:40AM	Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:47AM	Verve Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-02-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.24% -5.39%
07:07PM	Loading…
Jul-08-24 07:07PM	Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now? (Insider Monkey) +8.00% +10.76%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-01-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-28-24 07:00AM	Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors (GlobeNewswire)
May-31-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Verve Therapeutics Announces Leadership Update (GlobeNewswire)
May-30-24 04:01PM	Verve Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace) -6.27%
May-12-24 04:00PM	3 Underappreciated Stocks That Could 10x in 10 Years (InvestorPlace)
May-08-24 01:54PM	VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:10AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Verve Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 07:20AM	Verve moves forward with backup base editing therapy (BioPharma Dive)
07:00AM	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 (GlobeNewswire)
04:01PM	Loading…
May-03-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-19-24 10:30AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws (PR Newswire)
Apr-06-24 09:50AM	After a Serious Setback, Is Verve Therapeutics a Buy? (Motley Fool)
Apr-03-24 01:40PM	Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls (Zacks)
Apr-02-24 04:04PM	Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily) -34.95%
10:36AM	Verve Plunges To Record High After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily)
09:31AM	Verve Falls as Gene-Editing Trial Paused on Safety Issues (Bloomberg)
09:01AM	Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects (Investor's Business Daily)
07:35AM	UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics Announces Updates on its PCSK9 Program (GlobeNewswire)
03:03AM	Verve pauses base editing trial, shifts strategy after treatment side effect (BioPharma Dive)
Mar-28-24 04:51PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-01-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:02PM	Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023 (GuruFocus.com) +21.47%
08:03AM	Verve Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-19-24 04:08PM	3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential (InvestorPlace)
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -9.23%
Feb-12-24 08:30AM	2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare (Motley Fool) +8.31%
Feb-01-24 06:30AM	Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-31-24 12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace) -5.66%
Jan-04-24 08:00AM	Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024 (Investor's Business Daily)
Jan-02-24 06:30AM	Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 12:00PM	Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade (Zacks) -6.76%
09:55AM	Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet (Zacks)
Dec-13-23 09:55AM	Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to Trade (Zacks) +9.82%
Dec-06-23 12:31PM	Hedge Fund and Insider Trading News: Palliser Capital, Balyasny Asset Management , Millennium Management, Blackwells Capital, Pantera Capital, NCR Voyix Corp (VYX), Verve Therapeutics, Inc. (VERV), and More (Insider Monkey) +7.95%
Dec-01-23 04:00PM	Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement (GlobeNewswire)
Nov-28-23 10:37PM	Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire) -6.12%
04:01PM	Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
Nov-27-23 09:55AM	Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect? (Zacks)
Nov-20-23 04:26PM	Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire) +5.37% -7.44%
Nov-17-23 03:41PM	Why Verve Therapeutics Stock Crashed as Much as 30% This Week (Motley Fool) +6.83%
Nov-16-23 05:41AM	Verve Therapeutics: Why Great Results Aren't Enough (Motley Fool)
05:20AM	After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy? (Motley Fool)
Nov-13-23 07:20PM	Heart Disease Breakthrough by Gene-Editor Verve Knocks Its Stock for a Loop (Barrons.com) -40.83% +15.93%
04:03PM	Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug (Investor's Business Daily)
02:28PM	Rebel's Edge - November 13: $BA, $VERV, $MNDY, and Harbaugh Stealing Signs (TheStreet.com)
12:17PM	Verve Therapeutics, Immersion fall; Tower Semiconductor, Boeing rise, Monday, 11/13/2023 (Associated Press Finance)
12:07PM	These 2 Stocks Are Making Big Monday Moves (Motley Fool)
08:56AM	Why Is Verve Therapeutics (VERV) Stock Down 39% Today? (InvestorPlace)
Nov-12-23 03:30PM	Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
10:34AM	First look at Verve study data offer base editing proof of principle (BioPharma Dive)
Nov-09-23 09:55AM	Wall Street Analysts Predict a 160.72% Upside in Verve Therapeutics (VERV): Here's What You Should Know (Zacks)
08:00AM	1 Cathie Wood Stock to Buy Hand Over Fist Right Now (Motley Fool)
05:57AM	2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher (Motley Fool)
Nov-07-23 07:56AM	Verve Therapeutics Inc (VERV) Reports Q3 2023 Financial Results (GuruFocus.com) +24.83%
06:36AM	Verve Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-01-23 07:06AM	Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains? (Zacks)
05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +27.95%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
06:01AM	Verve and Lilly Relationship Expands to Include Verve's In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey) +6.45%
08:30AM	With 1 Roadblock Down, Is Verve Therapeutics a Buy Now? (Motley Fool)
Oct-25-23 01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-23-23 07:38AM	Verve Surges After FDA Lifts Hold on Gene-Editing Therapy (Bloomberg)
06:30AM	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Oct-10-23 09:45AM	2 Incredible Growth Stocks Near 52-Week Lows to Buy Now (Motley Fool)
Sep-27-23 07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-23 06:30AM	Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Associations Scientific Sessions 2023 (GlobeNewswire) +13.75%
Sep-21-23 04:05PM	Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 06:30AM	Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer (GlobeNewswire)

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kathiresan Sekar	Chief Executive Officer	Jun 28 '24	Option Exercise	2.87	30,000	86,100	351,128	Jul 02 07:30 AM
Ashe Andrew D.	See Remarks	May 14 '24	Buy	6.26	76,000	475,760	342,509	May 15 05:30 PM
Nickerson Joan	Chief Administrative Officer	Apr 02 '24	Sale	8.24	1,514	12,475	8,659	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Nov 29 '23	Sale	11.45	554	6,343	4,060	Dec 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERV

Verve Therapeutics Inc

Upgrade your FINVIZ experience